{
    "nctId": "NCT01100489",
    "briefTitle": "Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer",
    "officialTitle": "A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Tubular Ductal Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Ipsilateral breast tumor recurrence rates",
    "eligibilityCriteria": "Inclusion\n\n* Patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm)\n* All radiographically suspicious lesions must be biopsied and have histologically confirmed ductal carcinoma in-situ, invasive ductal, invasive lobular, medullary, papillary, colloid (mucinous), or tubular histologies\n* A maximum of two radiographically detected malignant lesions\n* Clinical Stage I-II breast carcinoma, with lesion size =\\< 5 cm for the dominant mass and the second lesion detected only on MRI, treated with lumpectomies; the MRI detected lesion must be pathologically =\\< 1 cm\n* Axillary lymph node evaluation, either sentinel lymph node biopsy or axillary dissection as deemed appropriate by the treating surgeon for all patients with invasive cancer; no axillary lymph node sampling is needed for patients with DCIS\n* Negative resection margins with at least a 2 mm margin from invasive and in-situ cancer or a negative re-excision\n* A posterior margin =\\< 2 mm from DCIS is permissible provided fascia was taken\n* Patients are eligible regardless of estrogen receptor, progesterone receptor, or Her-2/neu amplification\n* Hormonal therapy is allowed; if adjuvant chemotherapy is planned, the chemotherapy should be delivered first and radiation must begin no earlier than three weeks and no later than eight weeks following completion of chemotherapy\n* Signed study-specific informed consent prior to study entry\n\nExclusion\n\n* Extensive intraductal component by the Harvard definition (i.e., more than 25% of the invasive tumor is DCIS and DCIS present in adjacent breast tissue)\n* Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically confirmed negative\n* Patients receiving neoadjuvant chemotherapy\n* Patients with distant metastatic disease detected by radiographic imaging; specific studies for systemic imaging should be obtained as directed by localized symptoms or per available NCCN guidelines\n* Patients with known BRCA 1/BRCA 2 mutations or those with predicted risk of carrying the mutation by BRCAPRO (44) risk assessment \\>= 50%\n* Diffuse calcifications throughout the breast\n* Patients with skin involvement or inflammatory breast cancer\n* Patients with Paget's disease of the nipple\n* Patients nonepithelial breast malignancies such as lymphoma or sarcoma\n* Patients with collagen vascular disorders, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis\n* Patients with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent\n* Other malignancy, except non-melanomatous skin cancer, \\< 5 years prior to participation in this study\n* Patients who are pregnant or lactating, due to potential fetal exposure to radiation and unknown effects of radiation on lactating females",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}